Synaptic Institute
- Ketamine Therapy
- Psychedelic Therapy
- Hormone Replacement Therapy (HRT)
Portland, OR
Psychedelic Therapy clinics in Portland
Portland has 6 providers offering psychedelic therapy, with ketamine-assisted psychotherapy as the dominant nationwide option. Ketamine is FDA-approved as an anesthetic and Spravato (esketamine) is FDA-approved for treatment-resistant depression, while ketamine-assisted psychotherapy (KAP) is practiced off-label by licensed clinicians. Oregon's Measure 109 makes Oregon one of only two states with a regulated psilocybin services program, alongside Colorado. Licensed service centers operate under OHA oversight, with sessions typically running 2,000 to 3,500 dollars and requiring pre session preparation and post session integration. Ketamine-assisted psychotherapy is also widely available through medical clinics. Portland clinics commonly pair ketamine infusions or IM injections with therapy sessions, typical packages run 2,500 to 6,000 dollars for a six-session protocol, and Spravato is covered by many insurers when criteria are met. Psilocybin and MDMA remain federally illegal, and the FDA issued a Complete Response Letter to Lykos Therapeutics in August 2024 for MDMA-assisted therapy for PTSD. A reputable Portland provider will screen for cardiovascular risk, psychiatric history, and concurrent medications before starting treatment.
NW Regen
- PRP Therapy
- Arthritis Treatment
- Migraine Treatment
- Psychedelic Therapy
- Erectile Dysfunction (ED) Treatment
Regulatory context
A note on Oregon's psychedelic therapy rules.
Ketamine is a DEA Schedule III controlled substance, FDA-approved as a dissociative anesthetic and used off-label for treatment-resistant depression, PTSD, and chronic pain. The FDA approved esketamine (Spravato) in 2019 for treatment-resistant depression under a Risk Evaluation and Mitigation Strategy (REMS) program that requires in-office administration at certified sites. MDMA-assisted therapy remains Schedule I; the FDA issued a Complete Response Letter in August 2024 to Lykos Therapeutics on its MDMA new drug application. Psilocybin is Schedule I and holds FDA Breakthrough Therapy designation through sponsors such as Compass Pathways and Usona, but has not received FDA approval. Oregon Measure 109 (passed 2020, operational 2023) created a state psilocybin service center framework, and Colorado Proposition 122 (2022) authorized regulated healing centers.
-
Oregon Measure 109 / Psilocybin Services Act (2020, operational January 2023)
Established the nation's first regulated psilocybin therapy framework, with state-licensed Service Centers, Facilitators, manufacturers, and testing laboratories overseen by the Oregon Health Authority Psilocybin Services Section. -
Measure 110 / Drug Addiction Treatment and Recovery Act (2020, partially repealed 2024)
Decriminalized personal possession of small amounts of all drugs including psilocybin and MDMA; partially repealed in 2024 re-criminalizing possession as a misdemeanor. -
Oregon Uniform Controlled Substances Act
Mirrors federal scheduling outside the Psilocybin Services framework.
Oregon Psilocybin Services centers have been operational since 2023, with facilitators and service centers licensed statewide. The Oregon Health Authority Psilocybin Services Section oversees licensure, product testing, facilitator training, and facility standards. Federal psilocybin Schedule I status remains unchanged, but DEA has not brought enforcement actions against Measure 109-compliant operations to date. The Oregon Medical Board regulates ketamine prescribing.